NUWE:NASDAQ, Nuwellis, Inc.
Why NUWE stock fell on November 20
Nuwellis, Inc. fell 10.5%
on Friday, November 20, 2026, on 8,988 shares.
The headline around the move:
NUWE stock overview
Nuwellis, Inc. (NUWE:NASDAQ) closed at $3.41 on November 20, 2026,
down 10.50% on the day.
The stock trades 99.8% below its 52-week high of $1,556.10
and 35.3% above its 52-week low of $2.52.
Nuwellis, Inc. is part of the Health Care sector.
Key figures
- Price
- $3.41
- Day change
- -10.50%
- Volume
- 8,988
- Average volume
- 829,430
- Market cap
- 1M+
- 52-week range
- $2.52 – $1,556.10
- 50-day average
- $5.79
- 200-day average
- $174.57
Price action over the past year
In 250 trading sessions since November 20, 2025, NUWE closed higher on 81 days (32%).
Its best day was July 30, 2026 (+135.45%) and its worst was July 31, 2026 (-60.90%).
The stock moved 10% or more in a single session 37 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
NUWE news
-
Nov 19, 2026:
Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients
-
Nov 12, 2026:
Nuwellis (NUWE) Q3 2026 Earnings Call Transcript
-
Nov 12, 2026:
Nuwellis, Inc. Q3 2026 Earnings Call Summary
-
Nov 12, 2026:
Nuwellis Cuts Costs And Files Pediatric 510(K), But Flat Sales, Slowing Console Placements And Dilution Remain The Core Problem
-
Nov 12, 2026:
Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
-
Nov 10, 2026:
Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
-
Nov 10, 2026:
Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
-
Nov 5, 2026:
Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow Indication to Include Pediatric Patients Weighing 5 kg and Above
About Nuwellis, Inc.
Nuwellis Inc is a medical device company. Its solutions include Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flow, automatically displaying real-time data to the medical staff.
Similar stocks
Find more stocks like NUWE with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.